Xeris Biopharma Holdings (XERS) Retained Earnings (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Retained Earnings came in at -$24000.0 in Q1 2026, up 4.0% YoY from -$23076.9 in Q1 2025, and down 100.0% on a QoQ basis from $685.0 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Retained Earnings (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Retained Earnings data on file, last reported at -$24000.0 in Q1 2026.
- Quarterly Retained Earnings rose 4.0% year-over-year to -$24000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24000.0 (up 4.0% YoY) and the FY2025 annual result came in at $685.0 million, up 6.66% from the prior year.
- Retained Earnings fell to -$24000.0 in Q1 2026, from $685.0 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $685.0 million in Q4 2025 to a low of -$683.0 million in Q2 2025.
- A 5-year average of -$135.0 million and a median of -$52000.0 in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings jumped 221.84% — and 2025, when it slumped 2203125.81%.
- Tracing XERS's Retained Earnings over 5 years: stood at -$554.8 million in 2022, then fell by 11.22% to -$617.0 million in 2023, then surged by 204.09% to $642.3 million in 2024, then advanced by 6.66% to $685.0 million in 2025, then plunged by 100.0% to -$24000.0 in 2026.
- The last three Retained Earnings figures came in at -$24000.0 (Q1 2026), $685.0 million (Q4 2025), and -$682.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 3.75 Bn |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | -700.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -700.17 Mn |
| Mar 31, 2026 | -24,000.00 |
| Dec 31, 2025 | 685.00 Mn |
| Sep 30, 2025 | -682.39 Mn |
| Jun 30, 2025 | -683.00 Mn |
| Mar 31, 2025 | -25,000.00 |
| Dec 31, 2024 | 642.26 Mn |
| Sep 30, 2024 | 638.43 Mn |
| Jun 30, 2024 | -31,000.00 |
| Mar 31, 2024 | -636.01 Mn |
| Dec 31, 2023 | -617.03 Mn |
| Sep 30, 2023 | -603.64 Mn |
| Jun 30, 2023 | -591.45 Mn |
| Mar 31, 2023 | 601.67 Mn |
| Dec 31, 2022 | -554.77 Mn |
| Sep 30, 2022 | -37,000.00 |
| Jun 30, 2022 | -52,000.00 |
| Mar 31, 2022 | -493.80 Mn |
| Dec 31, 2021 | -460.11 Mn |
| Sep 30, 2021 | -409.30 Mn |